FPA144

Five Prime Therapeutics Inc (Nasdaq: FPRX) revealed that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to its FPA144 for gastric cancer treatment. That included cancer of the gastroesophageal junction in patients whose tumors over express FGFR2b. According to the...